Wainberg, Z. A., Wang, L., Yue, H., Motwani, M., Kasichayanula, S., Blaney, M. E., … Strickler, J. H. (2018). ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev. In Journal of Clinical Oncology (Vol. 36, pp. TPS3619–TPS3619). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps3619

Wainberg, Zev A., Lan Wang, Huibin Yue, Monica Motwani, Sreeneeranj Kasichayanula, Martha Elizabeth Blaney, Louie Naumovski, and John H. Strickler. “ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.” In Journal of Clinical Oncology, 36:TPS3619–TPS3619. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps3619.

Wainberg ZA, Wang L, Yue H, Motwani M, Kasichayanula S, Blaney ME, et al. ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS3619–TPS3619.

Wainberg, Zev A., et al. “ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS3619–TPS3619. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps3619.

Wainberg ZA, Wang L, Yue H, Motwani M, Kasichayanula S, Blaney ME, Naumovski L, Strickler JH. ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS3619–TPS3619.